Koss-Olinger Consulting’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-2,174
Closed -$262K 224
2026
Q1
$262K Sell
2,174
-1,175
-35% -$136K 0.02% 228
2025
Q4
$353K Sell
3,349
-1,340
-29% -$126K 0.03% 199
2025
Q3
$371K Hold
4,689
0.03% 241
2025
Q2
$371K Buy
4,689
+5
+0.1% +$397 0.03% 242
2025
Q1
$420K Buy
+4,684
New +$437K 0.04% 221
2024
Q4
Sell
-2,925
Closed -$332K 257
2024
Q3
$332K Buy
2,925
+62
+2% +$7.37K 0.03% 214
2024
Q2
$354K Buy
+2,863
New +$369K 0.03% 190
2024
Q1
Sell
-5,157
Closed -$562K 212
2023
Q4
$562K Sell
5,157
-1,465
-22% -$152K 0.06% 136
2023
Q3
$682K Sell
6,622
-175
-3% -$18.9K 0.1% 113
2023
Q2
$784K Hold
6,797
0.09% 107
2023
Q1
$723K Sell
6,797
-106
-2% -$11.4K 0.09% 108
2022
Q4
$766K Sell
6,903
-10,823
-61% -$1.11M 0.11% 95
2022
Q3
$1.53M Sell
17,726
-2,305
-12% -$206K 0.26% 31
2022
Q2
$1.83M Sell
20,031
-2,769
-12% -$245K 0.33% 25
2022
Q1
$1.87M Buy
22,800
+135
+0.6% +$10.6K 0.3% 29
2021
Q4
$1.74M Sell
22,665
-4,126
-15% -$329K 0.27% 29
2021
Q3
$2.01M Buy
26,791
+808
+3% +$61.5K 0.33% 25
2021
Q2
$2.02M Buy
25,983
+555
+2% +$41.3K 0.3% 36
2021
Q1
$1.87M Buy
+25,428
New +$1.88M 0.32% 34

Other funds holding MRK

Koss-Olinger Consulting's MRK Position: Q2 2026 in Review

Koss-Olinger Consulting sold out of Merck (MRK) in Q2 2026, closing a stake of 2,174 shares — an estimated $262K sold.

Koss-Olinger Consulting first reported a position in MRK in Q1 2021 and held it in 19 quarters. The position peaked at $2.02M in Q2 2021. 3,834 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Koss-Olinger Consulting reported no remaining Merck position as of Q2 2026 after selling out during the quarter.
  • Koss-Olinger Consulting sold 2,174 Merck shares in Q2 2026, an estimated $262K.
  • Koss-Olinger Consulting first reported a position in Merck in Q1 2021 and held it in 19 quarters.
  • Koss-Olinger Consulting's Merck position peaked at $2.02M in Q2 2021.
  • 3,834 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Koss-Olinger Consulting's 13F filing for Q2 2026, filed 10 Aug 2026.